HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.

AbstractBACKGROUND:
Primary antibody deficiencies (PADs) are the most prevalent primary immunodeficiencies. More severe forms of PADs-common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA)-require immunoglobulin replacement therapy (IRT) and may have serious complications. Differentiating severe PAD from milder hypogammaglobulinemia not requiring IRT can involve prolonged evaluations and treatment discontinuation. Severe PAD is defined by plasma cell deficiency, but this requires a biopsy to establish. Serum B-cell maturation antigen (sBCMA) is elevated in multiple myeloma, but levels are reduced among patients with myeloma in remission who have hypogammaglobulinemia.
OBJECTIVE:
To measure the sBCMA level in 165 subjects to determine whether it differentiates severe PAD-CVID and XLA-from less severe forms not requiring IRT and those without PAD.
METHODS:
sBCMA, B cells, and tissue plasma cells were measured among subjects with and without PAD, and correlated to clinical and laboratory data.
RESULTS:
Subjects with an IgG level of less than 600 mg/dL had reduced sBCMA levels compared with subjects with PAD with IgG levels of greater than or equal to 600 mg/dL and controls without PAD. sBCMA level was lower in patients with CVID and XLA compared with patients with IgA or IgG deficiency and controls. sBCMA level correlated with gastrointestinal plasma cells. sBCMA level of less than 15 ng/mL had 97% positive predictive value for CVID or XLA, whereas 25 ng/mL or more had an 88% negative predictive value.
CONCLUSIONS:
sBCMA level is profoundly reduced in patients with severe PAD, including those with CVID and XLA and those with IgG levels of less than 600 mg/dL. sBCMA level measurement has potential to augment clinical evaluation of PAD. Prospective studies are needed to evaluate sBCMA for new PAD diagnosis and determine the necessity of IRT.
AuthorsPaul J Maglione, Huaibin M Ko, Minami Tokuyama, Gavin Gyimesi, Camilia Soof, Mingjie Li, Eric Sanchez, Haiming Chen, Lin Radigan, James Berenson, Charlotte Cunningham-Rundles
JournalThe journal of allergy and clinical immunology. In practice (J Allergy Clin Immunol Pract) Vol. 8 Issue 1 Pg. 283-291.e1 (01 2020) ISSN: 2213-2201 [Electronic] United States
PMID31430592 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • B-Cell Maturation Antigen
Topics
  • Agammaglobulinemia (diagnosis)
  • B-Cell Maturation Antigen
  • Common Variable Immunodeficiency (diagnosis)
  • Humans
  • Primary Immunodeficiency Diseases
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: